원문정보
Development of Protein Drugs by PEGylation Technology
초록
영어
PEGylation, the attachment of polyethylene glycol (PEG) to proteins, is currently main technology for improving efficacy of protein drugs. This technology can prolong the plasma half-life, augment the in vivo stability, and diminish the immunogenicity of therapeutic proteins. Therefore, PEGylated proteins have the enhanced therapeutic efficacy and the reduced undesirable effects versus their native therapeutics. Since the first PEGylated protein product appeared on the market in the early 1990s, currently ten PEGylated protein products have been launched. These marketed drug products have proved the applicability and safety of the PEGylation technology. This review presents overview of PEGylation technology and addresses characteristics of PEGylation methods applied for the development of several protein drugs.
목차
1. 서론
2. PEGylation 효과
3. PEG의 특성과 유도체
4. 주요 PEG-단백질 의약품
4.1. PEG-adenosine deaminase (Adagen®)
4.2. PEG-asparaginase (Oncaspar®)
4.3. PEG-interferon alfa-2b (PEG-Intron®)
4.5. PEG-G-CSF (Neulasta®)
4.5. PEG-G-CSF (Neulasta®)
4.6. Pegvisomant (Somavert®)
4.7. Certolizumab pegol (Cimzia®)
5. 결론
감사
References